TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology

Rhea-AI Summary

TC Biopharm, a clinical-stage biotechnology company, has announced a strategic collaboration with The University of Texas MD Anderson Cancer Center as of January 17, 2023. This partnership aims to enhance understanding of gamma-delta T cells for cancer treatment over a three-year period. The collaboration will harness MD Anderson's clinical trial infrastructure alongside TC Biopharm's gamma-delta T cell oncology pipeline, focusing on preclinical and clinical studies. The initiative is expected to yield insights that will refine future studies and aid in the development of new cancer therapies, particularly in blood cancers and solid tumors.

Positive

• Collaboration with MD Anderson enhances research capabilities in gamma-delta T cell therapies.
• Potential for improved clinical insights and future study designs targeting various cancers.

Negative

• None.

• Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings

EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.

The collaboration brings together MD Anderson's clinical trial infrastructure and the translational research expertise of its immunotherapy platform with the clinical data of TC BioPharm's targeted gamma-delta T cell oncology pipeline. Under the terms of the three-year agreement, the research teams will work together on both preclinical and clinical studies to evaluate the potential for gamma-delta T cell therapies and to better understand the behaviors of these cells in patients.  The collaborators will form a six-person steering committee to drive the development of both the data set and subsequent assays for each study.

The comprehensive immunoprofiling capabilities of MD Anderson's immunotherapy platform will enable correlative studies on clinical samples to uncover detailed insights on the behavior of gamma-delta T cells and corresponding responses in patients. The platform is co-led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology, and James Allison, Ph.D., regental chair of Immunology.

Formulating a better picture of what is occurring in patients during gamma delta T cell therapies is expected to allow TC Biopharm to better design future studies as well as form a view towards future targeted cancer studies in other blood cancers and solid tumors potentially.

"We are enthusiastic about working with MD Anderson to further our knowledge of gamma delta T cells in order to help TC Biopharm develop future trials and treatments using our platform therapy OmnImmune," said Bryan Kobel, CEO of TC BioPharm. "This collaboration reinforces our mutual commitment to accelerating the discovery and development of cell therapies, and it highlights TC Biopharm's expertise in the gamma delta T cell space."

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns our manufacturing facility to maintain cost and product quality controls.

Forward Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-strategic-collaboration-to-advance-gamma-delta-t-cells-in-oncology-301722114.html

SOURCE TC BioPharm

FAQ

What is the purpose of TC Biopharm's collaboration with MD Anderson?

The collaboration aims to enhance understanding of gamma-delta T cells in oncology settings.

When was the partnership between TC Biopharm and MD Anderson announced?

The partnership was announced on January 17, 2023.

What will be the focus of TC Biopharm's studies with MD Anderson?

The focus will be on preclinical and clinical studies evaluating gamma-delta T cell therapies.

How long is the collaboration between TC Biopharm and MD Anderson expected to last?

The collaboration is expected to last for three years.

What therapies is TC Biopharm developing?

TC Biopharm is developing gamma-delta T cell therapies for cancer treatment.